![The Lancet Oncology in conversation with artwork](https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/4e/3e/ef/4e3eefcf-c4c6-a704-062b-d40be7b03ea7/mza_5325872108990078460.jpg/100x100bb.jpg)
Rosie Bradley on early-stage breast cancer treatment
The Lancet Oncology in conversation with
English - February 28, 2022 23:00 - 4 minutes - 3.16 MB - ★★★★★ - 1 ratingMedicine Health & Fitness Education cancer radiotherapy chemotherapy mrna Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Yi-Long Wu and Caicun Zhou on non-small-cell lung cancer
Rosie Bradley (Oxford Population Health, University of Oxford, Oxford, UK) discusses her Article on aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression.
Read the full article:
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv